Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Machine learning and AI have sparked a transformation in drug discovery, but cracking the biology is still paramount. That’s the thinking behind a new collaboration between UK startup Relation Therapeutics and GSK, which on Monday announced plans to explore multiple new targets…
Excited to see Relation launch two collaborations with GSK on fibrotic diseases and osteoarthritis. Relation will use their Lab-in-the-Loop preclinical data generation & AI platform to identify/validate targets for these diseases. https://t.co/oKFJGQZ7EH
$100M+ upfront, billion$ in milestone payments for potentially life-changing therapies from a company barely 5 years old. Lots of folks’ #AI + bio investments produce striking papers. @DCVC - family companies like @RelationRx produce striking *results*. https://t.co/T4dbVTgzNP
Aqemia, a Paris-based startup focused on drug discovery using quantum algorithms and AI, has raised an additional $38 million in funding, bringing its total to $100 million. This latest round was led by Cathay Innovation, following a €30 million raise in January 2024. The company aims to scale its drug discovery efforts by integrating theoretical physics with generative AI. Aqemia's funding milestone is part of a broader trend in the biotech and techbio sector, where AI and machine learning are increasingly utilized to revolutionize drug development processes. The company is expanding to London, UK, and plans to move towards clinical trials. Additionally, Aqemia's approach is exemplified by collaborations like that between Relation Therapeutics and GSK, focusing on fibrotic diseases and osteoarthritis.
